Artia Global Partners’s Sarepta Therapeutics SRPT Stock Holding History

Artia Global Partners’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-44,900	Closed	-$865K	–	70
2025 Q3	$865K	Buy	+44,900	New	+$800K	0.14%	45
2024 Q3	–	Sell	-2,600	Closed	-$411K	–	52
2024 Q2	$411K	Buy	+2,600	New	+$334K	0.08%	46
2023 Q4	–	Sell	-57,162	Closed	-$6.93M	–	35
2023 Q3	$6.93M	Sell	57,162 -20,000	-26%	-$2.26M	2.88%	11
2023 Q2	$8.84M	Buy	+77,162	New	+$9.95M	3.05%	12

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Artia Global Partners's SRPT Position: Q4 2025 in Review

Artia Global Partners sold out of Sarepta Therapeutics (SRPT) in Q4 2025, closing a stake of 44,900 shares — an estimated $865K sold.

Artia Global Partners first reported a position in SRPT in Q2 2023 and held it in 4 quarters. The position peaked at $8.84M in Q2 2023. 344 funds tracked by Wall St. Rank hold SRPT as of Q4 2025.

Artia Global Partners reported no remaining Sarepta Therapeutics position as of Q4 2025 after selling out during the quarter.
Artia Global Partners sold 44,900 Sarepta Therapeutics shares in Q4 2025, an estimated $865K.
Artia Global Partners first reported a position in Sarepta Therapeutics in Q2 2023 and held it in 4 quarters.
Artia Global Partners's Sarepta Therapeutics position peaked at $8.84M in Q2 2023.
344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2025.

Based on Artia Global Partners's 13F filing for Q4 2025, filed 17 Feb 2026.